Use of (i) an anti-CD3 antibody, (ii) an anti-CD56 antibody, (iii) an anti-CD14 antibody, (iv) an anti-CD38 antibody, (v) an anti-CD45 antibody, (vi) an anti-CD90 antibody, (vii) an anti- CD135 antibody, (viii) an anti-CD10 antibody, (ix) an anti-CD11c antibody, (x) an anti-CD19 antibody, (xi) an anti-CD34 antibody, (xii) an anti-CD45RA antibody, (xiii) an anti-CD7 antibody, (xiv) an anti-CD71 antibody, (xv) an anti-CD41/CD61 complex antibody or an anti- CD41 antibody and/or an anti-CD61 antibody (xvi) an anti-CD33 antibody and/or an anti- CD66b antibody, for identifying hematopoietic cell subtypes in an isolated sample, determining the relative frequency of hematopoietic cell subtypes in an isolated sample and/or quantifying the number of cells within hematopoietic cell subtypes in an isolated sample, wherein each of (i) to (xvi) is labelled with a different fluorochrome, wherein when (xvi) is an anti-CD33 antibody and an anti-CD66b antibody, the anti-CD33 antibody and anti-CD66b are labelled with the same fluorochrome, and wherein when (xv) is an anti-CD41 antibody and an anti-CD61 antibody, the anti-CD4 antibody and the anti-CD61 antibody are labelled with the same fluorochrome.
Methods are disclosed for forming bone and/or cartilage in an avian subject. The methods include administering to the avian subject a therapeutically effective amount of a composition comprising avian mesenchymal stem cells and a hydrogel that supports the differentiation of the avian mesenchymal stem cells into cells of an osteogenic and/or condrogenic lineage. In some embodiments, methods are disclosed for repairing a bone defect and preventing infection, such as that associated bone fracture, in an avian subject. The methods include administering locally to the bone defect a composition comprising a therapeutically effective amount of avian mesenchymal stem cells and a hydrogel, such as a methacrylated gelatin hydrogel.
Provided is a cocktail of factors for converting/reprogramming non-naïve pluripotent stem cells into TGFβ signaling-independent (TSI) naïve induced pluripotent stem cells (iPSCs). Also provided are methods for reprograming a non-naïve PSC into a TSI naïve iPSC by contacting the cell to be reprogrammed with effective amounts of compounds for a sufficient period of time to reprogram the cell into a TSI naïve iPSC.
The present invention provides a composition for inhibiting hair production in a mammal comprising an active polypeptide component and a pharmaceutically acceptable and/or cosmetically acceptable excipient, carrier or diluent. The invention further provides methods of inhibiting hair production in a mammal, e.g. human.
The present invention relates to compositions and methods utilizing hair follicle derived Non-Bulbar Dermal Sheath cells for use in the treatment of dental-related conditions, including the treatment of gingivitis. Briefly stated, the present invention provides compositions and methods for treating or preventing a wide variety of conditions associated with the oral cavity, including for example, periodontal disease and a variety of diseases or injuries associated with the gingiva utilizing hair follicle derived Non-Bulbar Dermal Sheath ("NDBS") cells. Within one aspect of the invention methods are provided for isolating NBDS cells, comprising the steps of: preparing vital hair and cleaving the hair.
The present disclosure provides, in part, compositions comprising peptides immunospecifically binds to MHC class I polypeptide-related sequence A (MICA).
A method and system of treating a disease for a patient, comprising assigning class data related to a class of patients that have characteristics similar to a specific patient and/or accessing patent data related to the specific patient; and optimizing a treatment plan, the optimizing being determined utilizing properties of a radiopharmaceutical used to treat the patient and the class data and/or the patient data.
Embodiments of the present invention are directed to methods of altering the surface of a substrate to improve cell adhesion, proliferation and/or differentiation on the surface of the substrate. Substrates within the scope of the present invention include implant surfaces where cell adhesion is desired and/or cellular growth and/or cellular differentiation on the substrate itself or at the location of the implant within the body.
Compositions, biologies and methods for injection into or near the pericardial space are provided. In some embodiments, a sustained release vehicle is used to deliver an active agent in a controlled manner to treat the heart of a subject. The sustained release vehicle may be, for example, a hydrogel particle. In certain embodiments, a vehicle may be used to deliver an active agent comprising a biological entity such as a virus or cell to the pericardial space. In certain embodiments, compositions and methods are provided for inhibiting formation of tissue adhesions within the pericardial space.